News

Affitech, an antibody R&D company, has reported that the European Patent Office has granted a European patent on the use of phagemid particles having an antibody-coliphage pIII fusion

Efient is a new antiplatelet agent that was granted marketing authorization by the European Commission on February 25, 2009, for the reduction of atherothrombotic events in patients with

Michael McManus, Jr, president and CEO of Misonix, said: “We are pleased to further strengthen our balance sheet with the additional $3.5 million in cash from the sale

Prior to joining TransMolecular, Mr Radie was executive vice president and chief business officer at Prestwick Pharmaceuticals, and vice president of project management and chief business officer at

Dr Lord comes to Navigenics from Louisville, Kentucky-based Humana, where as chief innovation officer he was responsible for designing new products and services to enable people to navigate

Dr Sable has served as resident and chief resident in obstetrics and gynecology at New York Hospital-Cornell Medical Center and as fellow in reproductive endocrinology at the Brigham

Mr Wolcott most recently served as president and COO of Dimicron, a medical company utilizing synthetic diamond for orthopedic applications, and previously as COO and director of Rubicon

Under the terms of the licensing agreement, BioWa grants Sanofi-Aventis non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent technology for an undisclosed number of

Mr Davis brings over 25 years of experience in global healthcare and medical devices markets and over 14 of those in the ophthalmic arena to Paradigm Medical Industries.